Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 33

Sort by

Sort Order Select

Journal Articles

Independent Prognostic Value of Flow Cytometry (FCM) in Myelodysplastic Syndromes (MDS) - Composition of a Prognostic FCM-Score for Overall Survival

Uta Oelschlaegel, Aida Santaolalla, Jessica A. Timms, Susann Winter, Katja Sockel, Martin Bornhäuser, Farzin Farzaneh, Claire N. Harrison, Theresia M. Westers, Arjan van de Loosdrecht, Mieke Van Hemelrijck, Uwe Platzbecker, Shahram Kordasti

Blood (2021) 138 (Supplement 1): 2603.

https://doi.org/10.1182/blood-2021-146367

Published: 2021

Journal Articles

Safety and Efficacy of AUTO1, a Fast-Off Rate CD19 CAR in Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma (B-NHL) and Chronic Lymphocytic Leukaemia (CLL)

Blood (2021) 138 (Supplement 1): 3823.

https://doi.org/10.1182/blood-2021-146316

Published: 2021

Journal Articles

ALLCAR19: Updated Data Using AUTO1, a Novel Fast-Off Rate CD19 CAR in Relapsed/Refractory B-Cell Acute Lymphoblastic Leukaemia and Other B-Cell Malignancies

Blood (2020) 136 (Supplement 1): 3–4.

https://doi.org/10.1182/blood-2020-137768

Published: 2020

Journal Articles

Automated Manufacture of Matched Donor-Derived Allogeneic CD19 CAR T-Cells for Relapsed/Refractory B-ALL Following Allogeneic Stem Cell Transplantation: Toxicity, Efficacy and the Important Role of Lymphodepletion

Blood (2019) 134 (Supplement_1): 776.

https://doi.org/10.1182/blood-2019-129640

Published: 2019

Journal Articles

Therapy of Paediatric B-ALL with a Fast Off Rate CD19 CAR Leads to Enhanced Expansion and Prolonged CAR T Cell Persistence in Patients with Low Bone Marrow Tumour Burden, and Is Associated with a Favourable Toxicity Profile

Blood (2019) 134 (Supplement_1): 225.

https://doi.org/10.1182/blood-2019-125009

Published: 2019

Journal Articles

AUTO1, a Novel Fast Off CD19CAR Delivers Durable Remissions and Prolonged CAR T Cell Persistence with Low CRS or Neurotoxicity in Adult ALL

Blood (2019) 134 (Supplement_1): 226.

https://doi.org/10.1182/blood-2019-131086

Published: 2019

Journal Articles

Allogeneic Anti-CD19 CAR T Cells Manufactured from Healthy Donors Provide a Unique Cellular Product with Distinct Phenotypic Characteristics Compared to CAR T Cells Generated from Patients with Mature B Cell Malignancies

Charlotte Graham, MRCP, BSc, MBBS, Agnieszka Jozwik, PhD, Ruby Quartey-Papafio, Nikolaos Ioannou, PhD MSc, BSc, Ana M Metelo, PhD, Carlo Scala, PhD, Glenda Dickson, PhD, Orla Stewart, Maria Almena-Carrasco, Elisa Peranzoni, Alan G. Ramsay, BSc,MSc,PhD, Sandra Dupouy, Pharm.D, PhD, Farzin Farzaneh, PhD, Piers E.M. Patten, BSc, MRCP, MRCPath, PhD, Andrea Pepper, PhD, Reuben Benjamin, FRCPath, MRCP, MBBS, PhD

Blood (2019) 134 (Supplement_1): 3228.

https://doi.org/10.1182/blood-2019-123018

Published: 2019

Journal Articles

Preliminary Results of UCART19, an Allogeneic Anti-CD19 CAR T-Cell Product, in a First-in-Human Trial (CALM) in Adult Patients with CD19 + Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia

Blood (2017) 130 (Supplement 1): 887.

https://doi.org/10.1182/blood.V130.Suppl_1.887.887

Published: 2017

Journal Articles

A Novel Low Affinity CD19CAR Results in Durable Disease Remissions and Prolonged CAR T Cell Persistence without Severe CRS or Neurotoxicity in Patients with Paediatric ALL

Blood (2017) 130 (Supplement 1): 806.

https://doi.org/10.1182/blood.V130.Suppl_1.806.806

Published: 2017

Journal Articles

Functional Characteristics of FAS-L Resistant and IL-2 Deprived Regulatory T Cells (Treg A) in Idiopathic Aplastic Anaemia

Benedetta Costantini, MD, Syed A Mian, PhD, Shok Ping Lim, PhD, Frederic Toulza, PhD, Stephen Orr, PhD, Pilar Perez-Abellan, MSc, Ander Abarrategi, PhD, Farzin Farzaneh, PhD, Dominique Bonnet, PhD, Judith Marsh, MD, Shahram Kordasti, MD PhD, Ghulam Mufti, DM, FRCP, FRCPath

Blood (2017) 130 (Supplement 1): 2450.

https://doi.org/10.1182/blood.V130.Suppl_1.2450.2450

Published: 2017

Journal Articles

Automated Manufacture of CAR19 Donor Lymphocytes Incorporated into an Escalated Dose DLI Protocol: Preliminary Results from the CARD Study

Blood (2017) 130 (Supplement 1): 1993.

https://doi.org/10.1182/blood.V130.Suppl_1.1993.1993

Published: 2017

Journal Articles

A Novel Second Generation CD19 CAR for Therapy of High Risk/Relapsed Paediatric CD19 + Acute Lymphoblastic Leukaemia and Other Haematological Malignancies: Preliminary Results from the Carpall Study

Sara Ghorashian, MD PhD FRCPath, Anne Marijn Kramer, MD, Sarah Jayne Albon, BSc, MSc, Catherine Irving, BSc, Lucas Chan, PhD, Fernanda Castro, PhD, Bilyana Popova, Kim Champion, PhD, Gary Wright, Hong Zhan, PhD, Waseem Qasim, MBBS PhD, Robert Wynn, Rachael Hough, MD BMBS, FRCP, FRCPath, Farzin Farzaneh, Martin A Pule, MD PhD, Persis J Amrolia, Professor

Blood (2016) 128 (22): 4026.

https://doi.org/10.1182/blood.V128.22.4026.4026

Published: 2016

Journal Articles

Donor Lymphocyte Infusions Correct Deficiency of Naive T Cells and Improve T-Cell Competence after Allogeneic Haematopoietic Stem Cell Transplantation with Lymphocyte Depletion

Monera Al Rukhayes, Victoria T Potter, Pilar Perez-Abellan, Jesus Feliu, Lajos Floro, Ruby Quartey-Papafio, Farzin Farzaneh, Pramila Krishnamurthy, Jennifer Clay, Carmel Rice, Antonio Pagliuca, MBBS MA FRCP FRCPath, Ghulam J Mufti, Linda D Barber

Blood (2016) 128 (22): 2233.

https://doi.org/10.1182/blood.V128.22.2233.2233

Published: 2016

Journal Articles

Deep phenotyping of Tregs identifies an immune signature for idiopathic aplastic anemia and predicts response to treatment

Blood (2016) 128 (9): 1193–1205.

https://doi.org/10.1182/blood-2016-03-703702

Published: 2016

Includes: Supplemental data

Journal Articles

Inhibition Of PI3K Classia Kinases Using GDC0941 Overcomes Protection Of Multiple Myeloma Cells In The Bone Marrow Microenvironment

Hugh Kikuchi, BSc, Amofa Eunice, PhD, Maeve McEnery, BSc, Farzin Farzaneh, DPhil, Stephen A Schey, MD, Yolanda Calle, PhD

Blood (2013) 122 (21): 3169.

https://doi.org/10.1182/blood.V122.21.3169.3169

Published: 2013

Journal Articles

Functional characterization of CD4 + T cells in aplastic anemia

Shahram Kordasti, Judith Marsh, Sufyan Al-Khan, Jie Jiang, Alexander Smith, Azim Mohamedali, Pilar Perez Abellan, Caroline Veen, Benedetta Costantini, Austin G. Kulasekararaj, Nana Benson-Quarm, Thomas Seidl, Syed A. Mian, Farzin Farzaneh, Ghulam J. Mufti

Blood (2012) 119 (9): 2033–2043.

https://doi.org/10.1182/blood-2011-08-368308

Published: 2012

Includes: Supplemental data

Journal Articles

Functional Characterization of CD4 + T-Cells in Aplastic Anemia (AA)

Shahram Y Kordasti, MD, PhD, Judith C. W. Marsh, Prof MD PhD, Sufyan Al-Khan, MD, Jie Jiang, PhD, Alexander E Smith, PhD, Azim M Mohamedali, PhD, Pilar Perez Abellan, Caroline Veen, Benedetta Costantini, MD, Nana Benson Quarm, Thomas Seidl, Syed A Mian, Farzin Farzaneh, DPhil, Ghulam J. Mufti, MD

Blood (2011) 118 (21): 1340.

https://doi.org/10.1182/blood.V118.21.1340.1340

Published: 2011

Journal Articles

CD80-IL2 Expressing Myeloma Cells for Immune Gene Therapy of Multiple Myeloma

Giulia Giunti, David Malone, Lucas Chan, Darling David, Shahram Y Kordasti, MD, PhD, Linda Barber, Oppenheim David, Farzin Farzaneh, DPhil, Stephen Schey

Blood (2011) 118 (21): 4718.

https://doi.org/10.1182/blood.V118.21.4718.4718

Published: 2011

Journal Articles

5-Azacytidine Specifically Depletes Regulatory T Cells (Tregs) in Myelodysplastic Syndrome (MDS) Patients

Benedetta Costantini, MD, Shahram Y Kordasti, MD, PhD, Austin G Kulasekararaj, MBBS, MD, MRCP, FRCP, Jie Jiang, PhD, Thomas Seidl, Pilar Perez Abellan, Janet Hayden, Farzin Farzaneh, DPhil, Ghulam J. Mufti, MD

Blood (2011) 118 (21): 787.

https://doi.org/10.1182/blood.V118.21.787.787

Published: 2011

Journal Articles

Apoptin Induced Tumour Specific Killing Via Protein Kinase C Isoforms: A Potential Therapeutic Strategy In Plasma Cell Dyscrasias

Jie Jiang, Daryl Cole, Sr., Nigel Westwood, Lee Macpherson, Farzin Farzaneh, Ghulam J. Mufti, DM, FRCP, FRCPath, Mahvash Tavassoli, Joop Gaken

Blood (2010) 116 (21): 5039.

https://doi.org/10.1182/blood.V116.21.5039.5039

Published: 2010

NARROW

Independent Prognostic Value of Flow Cytometry (FCM) in Myelodysplastic Syndromes (MDS) - Composition of a Prognostic FCM-Score for Overall Survival

Safety and Efficacy of AUTO1, a Fast-Off Rate CD19 CAR in Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma (B-NHL) and Chronic Lymphocytic Leukaemia (CLL)

ALLCAR19: Updated Data Using AUTO1, a Novel Fast-Off Rate CD19 CAR in Relapsed/Refractory B-Cell Acute Lymphoblastic Leukaemia and Other B-Cell Malignancies

Automated Manufacture of Matched Donor-Derived Allogeneic CD19 CAR T-Cells for Relapsed/Refractory B-ALL Following Allogeneic Stem Cell Transplantation: Toxicity, Efficacy and the Important Role of Lymphodepletion

Therapy of Paediatric B-ALL with a Fast Off Rate CD19 CAR Leads to Enhanced Expansion and Prolonged CAR T Cell Persistence in Patients with Low Bone Marrow Tumour Burden, and Is Associated with a Favourable Toxicity Profile

AUTO1, a Novel Fast Off CD19CAR Delivers Durable Remissions and Prolonged CAR T Cell Persistence with Low CRS or Neurotoxicity in Adult ALL

Allogeneic Anti-CD19 CAR T Cells Manufactured from Healthy Donors Provide a Unique Cellular Product with Distinct Phenotypic Characteristics Compared to CAR T Cells Generated from Patients with Mature B Cell Malignancies

Preliminary Results of UCART19, an Allogeneic Anti-CD19 CAR T-Cell Product, in a First-in-Human Trial (CALM) in Adult Patients with CD19 + Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia

A Novel Low Affinity CD19CAR Results in Durable Disease Remissions and Prolonged CAR T Cell Persistence without Severe CRS or Neurotoxicity in Patients with Paediatric ALL

Functional Characteristics of FAS-L Resistant and IL-2 Deprived Regulatory T Cells (Treg A) in Idiopathic Aplastic Anaemia

Automated Manufacture of CAR19 Donor Lymphocytes Incorporated into an Escalated Dose DLI Protocol: Preliminary Results from the CARD Study

A Novel Second Generation CD19 CAR for Therapy of High Risk/Relapsed Paediatric CD19 + Acute Lymphoblastic Leukaemia and Other Haematological Malignancies: Preliminary Results from the Carpall Study

Donor Lymphocyte Infusions Correct Deficiency of Naive T Cells and Improve T-Cell Competence after Allogeneic Haematopoietic Stem Cell Transplantation with Lymphocyte Depletion

Deep phenotyping of Tregs identifies an immune signature for idiopathic aplastic anemia and predicts response to treatment

Inhibition Of PI3K Classia Kinases Using GDC0941 Overcomes Protection Of Multiple Myeloma Cells In The Bone Marrow Microenvironment

Functional characterization of CD4 + T cells in aplastic anemia

Functional Characterization of CD4 + T-Cells in Aplastic Anemia (AA)

CD80-IL2 Expressing Myeloma Cells for Immune Gene Therapy of Multiple Myeloma

5-Azacytidine Specifically Depletes Regulatory T Cells (Tregs) in Myelodysplastic Syndrome (MDS) Patients

Apoptin Induced Tumour Specific Killing Via Protein Kinase C Isoforms: A Potential Therapeutic Strategy In Plasma Cell Dyscrasias

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only